A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: PIK3CA Mutated Advanced Solid Tumors|PIK3CA Amplified Advanced Solid Tumors
Interventions: DRUG: BYL719|DRUG: AMG 479
Sponsor: Novartis Pharmaceuticals
Collaborators: NantCell, Inc.